Abstract
Curcumin is the main secondary metabolite of Curcuma longa and other Curcuma spp, and has been reported to have some potential in preventing and treating some physiological disorders. This study investigated the effect of curcumin in inhibiting high-fat diet and streptozotocin (STZ)-induced hyperglycemia and hyperlipidemia in rats. Twenty-six male Sprague-Dawley (SD) rats (170–190 g) were randomly divided into a standard food pellet diet group (Control group), a high-fat diet and streptozotocin group (HF + STZ group), and a high-fat diet combined with curcumin and STZ group (HF + Cur + STZ group). Compared with the HF + STZ group, the HF + Cur + STZ group exhibited significantly reduced fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (AST), and aspartate transaminase (ALT) levels, as well as liver coefficients. In the livers of these rats, the expression of malondialdehyde (MDA) and Bax was downregulated, whereas that of superoxide dismutase (SOD) and Bcl-2 was upregulated. Moreover, the liver histology of these rats was improved and resembled that of the control rats. These results suggest that curcumin prevents high-fat diet and STZ-induced hyperglycemia and hyperlipidemia, mainly via anti-oxidant and anti-apoptotic mechanisms in the liver.
Highlights
Diabetes mellitus (DM) is common endocrine disease involving metabolic disorders on a global scale [1]
We investigated the inhibition of a high-fat diet with streptozotocin (STZ)-induced hyperglycemia and hyperlipidemia in rats by curcumin
Levels and Bax protein, but upregulated liver superoxide dismutase (SOD) levels and Bcl-2 protein while improving liver microstructures in high-fat diet and STZ-treated rats. These results suggest that curcumin prevents high-fat diet and STZ-induced hyperglycemia and hyperlipidemia via anti-oxidant and anti-apoptotic mechanisms in the liver
Summary
Diabetes mellitus (DM) is common endocrine disease involving metabolic disorders on a global scale [1]. According to the 2016 Global Report on Diabetes of the World Health. Organization (WHO), 422 million people (or 8.5% of the population) were suffering from DM globally. DM and its complications affect the quality of life of human beings, and have become a significant global public health problem [3]. Because of the continuous increase in the numbers of patients and aggravation in prevalence, DM is one of the major chronic noninfectious diseases worldwide, and has imposed a heavy burden on human beings [3]. Research and development of effective medicine for controlling DM and its complications is of great significance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
